A5038720672- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Hepatocellular Carcinoma Treatment and Prognosis
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gallbladder and Bile Duct Disorders
- Gastric Cancer Management and Outcomes
- Liver Disease Diagnosis and Treatment
- Kruppel-like factors research
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Treatments and Studies
- Eosinophilic Disorders and Syndromes
- Lung Cancer Treatments and Mutations
- Cancer, Lipids, and Metabolism
- Colorectal Cancer Surgical Treatments
- Liver Disease and Transplantation
- Cancer Genomics and Diagnostics
- Cytokine Signaling Pathways and Interactions
- Parasitic infections in humans and animals
- Acute Ischemic Stroke Management
- Cancer Mechanisms and Therapy
- Cardiac, Anesthesia and Surgical Outcomes
- Japanese History and Culture
- Autoimmune Bullous Skin Diseases
- Chronic Lymphocytic Leukemia Research
The Ohio State University Wexner Medical Center
2024-2025
Yokohama City University
2024-2025
Gunma Prefectural Institute of Public Health and Environmental Sciences
2025
Twitter (United States)
2025
Yokohama City University Medical Center
2024
Gunma University
2017-2024
Fujisawa City Hospital
2018-2023
Sierra Engineering (United States)
2023
Creative Commons
2022
Gilead Sciences (United States)
2013-2021
Abstract Introduction Approximately 61 million individuals in the United States have a disability and face unique challenges, resulting healthcare disparities. Objective We aimed to evaluate impact of on postoperative outcomes number healthy days at home (HDAH). Methods Patients who underwent surgery for gastrointestinal (GI) cancer between 2017 2020 were identified using Medicare database. Multivariable regression models used examine association complications, discharge disposition, HDAH....
Abstract Introduction While postoperative adjuvant chemotherapy (AC) is generally recommended for intrahepatic cholangiocarcinoma (ICC), its benefit remains debated. This study aimed to identify patients that may from AC following liver resection of ICC. Methods Patients who underwent ICC between 2000 and 2023 were identified an international multi-institutional database. Individual multivariable Cox models used evaluate the interaction each prognostic factor effect on survival. Results...
Abstract Momelotinib (MMB) is a JAK1/2 and ACVR1 inhibitor with demonstrated clinical activity in all 3 hallmarks of myelofibrosis (MF): anemia, constitutional symptoms, splenomegaly. In this phase 2 open-label translational biology study (NCT02515630) 41 transfusion-dependent patients MF, we explored mechanisms underlying the favorable MMB on MF-associated iron-restricted including its impact serum hepcidin levels, markers iron storage availability, erythropoiesis, inflammation. A...
Momelotinib, a small-molecule inhibitor of Janus kinase 1 and 2, has demonstrated efficacy in myelofibrosis patients with 300 mg, once-daily dosing. This open-label, non-randomized, phase 1/2 study evaluated the safety therapeutic benefit momelotinib twice-daily A total 61 subjects primary or post–polycythemia vera/post–essential thrombocythemia intermediate- high-risk disease received momelotinib. dose escalation identified 200 mg twice daily as optimal to be expanded 2. The most frequent...
Abstract Momelotinib is the first inhibitor of Janus kinase 1 (JAK1) and JAK2 shown to also inhibit activin A receptor type (ACVR1), a key regulator iron homeostasis, has demonstrated improvements in splenomegaly, constitutional symptoms, anemia myelofibrosis (MF). This long-term analysis pooled data from 3 randomized phase studies momelotinib (MOMENTUM, SIMPLIFY-1, SIMPLIFY-2), representing MF disease early (JAK inhibitor–naive) late inhibitor–experienced) stages. Patients control arms...
Bone marrow fibrosis (BMF) is a pathological feature of myelofibrosis, with higher grades associated poor prognosis. Limited data exist on the association between outcomes and BMF changes. We present from Janus kinase (JAK) inhibitor-naive patients SIMPLIFY-1 (NCT01969838), double-blind, randomized, phase 3 study momelotinib vs ruxolitinib. Baseline week 24 bone biopsies were graded 0 to as per World Health Organization criteria. Other assessments included Total Symptom Score, spleen volume,...
Abstract Background The feasibility of trials in liver surgery using a single-component clinical endpoint is low because single endpoints require large samples due to their incidence. current study sought develop and validate novel composite (CELS) facilitate the generation more feasible robust high-level evidence field surgery. Methods Patients who underwent curative-intent hepatectomy for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or colorectal metastasis were identified...
Objective: The aim of this study is to externally validate the original borderline resectability (BR) category for predicting overall survival (OS) in hepatocellular carcinoma (HCC) following resection and assess whether incorporating tumor burden score (TBS) other clinical factors could enhance predictive accuracy. Background: A recent Japanese expert panel introduced a new HCC classification scheme: resectable (R), 1 (BR1), 2 (BR2). Methods: Patients undergoing curative-intent hepatectomy...
Abstract Introduction The role of recurrence-free survival (RFS) as a validated surrogate endpoint for overall (OS) among patients undergoing upfront surgery intrahepatic cholangiocarcinoma (ICC) has not been defined. We sought to evaluate the correlation between RFS and OS after surgical resection ICC. hypothesized that was reliable with Methods Patients who underwent curative-intent ICC 2000 2023 were identified from an international, multi-institutional database. assessed using rank...
Liver resection for multifocal intrahepatic cholangiocarcinoma (ICC) remains controversial due to a poor prognosis, driven by aggressive tumour biology. The aim of this study was stratify ICC patients identify those who are likely benefit from resection. Patients underwent upfront curative-intent hepatectomy were identified an international multi-institutional database. Among with tumours, overall survival (OS) analysed using multivariable Cox regression prognostic factors. Tumour burden...
Abstract Background Existing models to predict recurrence-free survival (RFS) after hepatectomy for hepatocellular carcinoma (HCC) rely on static preoperative factors such as alpha-fetoprotein (AFP) and tumor burden score (TBS). These overlook dynamic postoperative AFP changes, which may reflect evolving recurrence risk. We sought develop a dynamic, real-time model integrating time-updated values with TBS improved prediction. Patients Methods undergoing curative-intent HCC (2000–2023) were...
Abstract Background Among patients with hepatocellular carcinoma (HCC), the impact of anatomic resection (AR) versus non-anatomic (NAR) on non-transplantable recurrence (NTR) remains poorly defined. We sought to compare risk NTR among treated AR NAR as primary surgical strategy for HCC. Patients and Methods HCC within Milan criteria who underwent curative-intent between 2000 2020 were identified from an international multi-institutional database. The inverse probability treatment weighting...
The oral activin A receptor type I, Janus kinase 1 (JAK1), and JAK2 inhibitor momelotinib demonstrated symptom, spleen, anemia benefits in intermediate- high-risk myelofibrosis (MF). Post hoc analyses herein evaluated the efficacy safety of patients with MF thrombocytopenia (platelet counts <100 × 109/L) from randomized phase 3 studies: MOMENTUM (momelotinib versus danazol; JAK experienced); SIMPLIFY-1 ruxolitinib; naïve); SIMPLIFY-2 best available therapy; these studies were not...
7002 Background: MMB, an oral JAK1/2 and ACVR1/ALK2 inhibitor, showed clinical activity on MF symptoms, RBC transfusion requirements (anemia), spleen volume in the SIMPLIFY trials. This pivotal phase 3 study of patients (pts) previously treated with a JAK inhibitor (JAKi) tested MMB vs DAN key symptom, anemia, endpoints at 24 weeks (wks). Methods: Eligibility: Primary or post-ET/PV MF; DIPSS high risk, Int-2, Int-1; Symptom Assessment Form Total Score (MFSAF TSS) ≥10; Hgb <10 g/dL; prior...